IP Library Granted Patent US 7,130,835
Granted Patent B2
US 7,130,835 · App. 10/327,229 · Granted Oct 31, 2006

System and method for predictive ophthalmic correction

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,130,835
App. No.
10/327,229
Granted
Oct 31, 2006
Kind
B2
Abstract

A system and method for providing a predictive outcome in the form of a predictive best instruction for a therapeutic ophthalmic correction of a patient's vision defects. The predictive best instruction is derived from prospective therapeutic-outcome-influencing, new information that is analyzed in conjunction with optimized, historical therapeutic-outcome information. The instruction is preferably an optimized, custom, photoablative algorithm for driving a photoablative, excimer laser. The instruction can be provided on a fee basis.

Claims (80)

1. A system that provides a predictive outcome for a proposed therapeutic ophthalmic correction, comprising:

a collecting and transmitting station for collecting a prospective, therapeutic-outcome-influencing, new information metric relating to at least one of a patient, a practitioner, a diagnostic measurement, a therapeutic condition, and an environmental condition, and for transmitting said plurality of new information to a computing station, wherein said computing station includes means for

a) receiving said new information metric,

b) storing a plurality of optimized historical therapeutic-outcome information derived from an optimization analysis of prospective therapeutic-outcome-influencing, historical information relating to at least one of a patient, a practitioner, a diagnostic measurement, a therapeutic condition, and an environmental condition, and

c) providing an output comprising a predictive best instruction that is derived from an analysis of the new information in conjunction with the optimized historical information to facilitate an improved therapeutic ophthalmic correction.

2. The system of claim 1 , wherein the predictive best instruction is an algorithm that describes a laser ablation shot placement pattern on a patient's eye.

3. The system of claim 1 , wherein the predictive best instruction comprises an outcome-predictive, ophthalmic information metric suited for use by a practitioner for providing the therapeutic ophthalmic correction.

4. The system of claim 1 , wherein the optimization analysis is a statistical analysis.

5. The system of claim 1 , wherein the optimization analysis is a matrix analysis comprising a vector, Z, representing new diagnostic information, a clinical matrix, M′, representing an interdependence relationship of a plurality of Zernike terms or their equivalents, another matrix, M″, representing historical outcome information, and a resultant matrix, Z′, representing the predictive best instruction.

6. The system of claim 5 , further comprising a feedback loop provided by an updating information metric supplied to the matrix M″.

7. The system of claim 5 , wherein the components of M″ represent information from a plurality of sources.

8. The system of claim 5 , wherein the components of Z are Zernike vectors or their equivalents output from a wavefront sensor device.

9. The system of claim 4 , wherein the computing station comprises a data structure employing a neural network for generating the predicted best instruction.

10. The system of claim 1 , wherein the predicted best instruction is a postoperative spherical aberration value, Z 400Post , for a given pupil size.

11. The system of claim 10 , wherein the postoperative spherical aberration value, Z 400Post , is exclusively dependent upon a preoperative spherical aberration value, Z 400Pre , a preoperative defocus value, Z 200Pre , and a constant factor, ±C.

12. The system of claim 11 , wherein Z 400Post =A*Z 400Pre +B*Z 200Pre +C, where A, B are (±) constants for the given pupil size.

13. The system of claim 1 , wherein the computing station is in physical proximity to the collecting and transmitting station.

14. The system of claim 1 , wherein the computing station is located remotely from the collecting and transmitting station.

15. A system that provides a predictive outcome for a therapeutic ophthalmic correction, comprising a computing station having a data structure that contains an optimized historical therapeutic-outcome information metric derived from an optimization analysis of a plurality of prospective therapeutic-outcome-influencing, historical information metrics, wherein the computing station is programmed to receive a plurality of prospective therapeutic-outcome-influencing, new information including at least ophthalmic defect information about a patient, wherein said computing station is further programmed to provide in a suitable form an outcome-predictive best instruction based upon an analysis of the new information in conjunction with the historical outcome information.

16. The system of claim 15 , wherein the data structure comprises a neural network.

17. The system of claim 15 , wherein the outcome-predictive best instruction is an algorithm that describes a laser ablation shot placement pattern on a patient's eye.

18. The system of claim 15 , wherein the outcome-predictive best instruction is a postoperative spherical aberration value, Z 400Post , for a given pupil size.

19. The system of claim 18 , wherein the postoperative spherical aberration value, Z 400Post , is exclusively dependent upon a preoperative spherical aberration value, Z 400pre , a preoperative defocus value, Z 200Pre , and a constant factor, ±C.

20. The system of claim 19 , wherein Z 400Post =A*Z 400Pre +B*Z 200Pre +C, where A, B are (±) constants for the given pupil size.

21. The system of claim 15 , wherein the optimization analysis is a statistical analysis.

22. The system of claim 21 , wherein the optimization analysis is a matrix analysis comprising a vector, Z, representing new diagnostic information, a clinical matrix, M′, representing an interdependence relationship of a plurality of Zernike terms or their equivalents, another matrix, M″, representing historical outcome information, and a resultant matrix, Z′, representing the predictive best instruction.

23. The system of claim 22 , further comprising a feedback loop provided by an updating information metric supplied to the matrix M″.

24. The system of claim 22 , wherein the components of M″ represent information from a plurality of sources.

25. The system of claim 22 , wherein the components of Z are Zernike vectors or their equivalents output from a wavefront sensor device.

26. A system that provides a predictive outcome for a therapeutic ophthalmic correction, comprising:

a) a diagnostic station that acquires a new, ophthalmic information metric from a patient and export the new information metric;

b) a data collection and transfer station cooperatively engaged with the diagnostic station that receives and further exports the new information metric;

c) a computing station communicatively engaged with the data collection and transfer station, said computing station including a data structure containing optimized historical therapeutic-outcome information, programmed to receive and transmit information and to analyze each respective new information metric in conjunction with the optimized historical therapeutic-outcome information and, further, to generate a predictive best instruction; and

d) a therapeutic station cooperatively engaged with the computing station, having a capability to execute the predictive best instruction.

27. The system of claim 26 , wherein the data structure comprises a neural network.

28. The system of claim 26 , wherein the outcome-predictive best instruction is an algorithm that describes a laser ablation shot placement pattern on a patient's eye.

29. The system of claim 26 , wherein the outcome-predictive best instruction is a postoperative spherical aberration value, Z 400Post , for a given pupil size.

30. The system of claim 29 , wherein the postoperative spherical aberration value, Z 400Post , is exclusively dependent upon a preoperative spherical aberration value, Z 400Pre , a preoperative defocus value, Z 200Pre , and a constant factor, ±C.

31. The system of claim 30 , wherein Z 400Post =A*Z 400pre +B*Z 200Pre +C, where A, B are (±) constants for the given pupil size.

32. The system of claim 26 , wherein the optimization analysis is a statistical analysis.

33. The system of claim 32 , wherein the optimization analysis is a matrix analysis comprising a vector, Z, representing new diagnostic information, a clinical matrix, M′, representing an interdependence relationship of a plurality of Zernike terms or their equivalents, another matrix, M″, representing historical outcome information, and a resultant matrix, Z′, representing the predictive best instruction.

34. The system of claim 33 , further comprising a feedback loop provided by an updating information metric supplied to the matrix M″.

35. The system of claim 33 , wherein the components of M″ represent information from a plurality of sources.

36. The system of claim 33 , wherein the components of Z are Zernike vectors or their equivalents output from a wavefront sensor device.

37. A method for providing a predictive outcome for a therapeutic ophthalmic correction, comprising:

a) collecting a therapeutic-outcome-influencing, new information metric including at least ophthalmic defect information about a patient;

b) analyzing said new information in conjunction with a plurality of optimized, historical therapeutic outcome information for the determined ophthalmic defect; and

b) generating, via the computing device, a predictive best instruction for facilitating an optimized outcome of the ophthalmic therapeutic correction.

38. The method of claim 37 , further comprising utilizing the generated predictive best instruction to drive a therapeutic system for providing the ophthalmic correction.

39. The method of claim 37 , wherein the collecting step comprises automatically collecting the new information metric.

40. The method of claim 37 , wherein the generating step comprises a statistical analysis.

41. The method of claim 37 , wherein the generating step comprises calculating a resultant matrix, Z′, representing the predictive best instruction, from a vector, Z, representing the new diagnostic information, a clinical matrix, M′, representing an interdependence relationship of a plurality of Zernike terms or their equivalents, and another matrix, M″, representing the historical outcome information.

42. A method for providing a predictive outcome for a therapeutic ophthalmic correction, comprising:

a) obtaining a new information metric, said new information metric relating to an ophthalmic defect condition of a patient;

b) maintaining a database of optimized, historical ophthalmic outcome information, said ophthalmic outcome information being related to the ophthalmic defect condition; and

c) providing a predictive best instruction for the therapeutic ophthalmic correction, wherein the predictive best instruction is provided on a transactional basis.

43. The method of claim 42 , wherein the step of obtaining a new information metric comprises collecting wavefront aberration data from a wavefront sensor device.

44. The method of claim 42 , wherein the step of maintaining a database of optimized, historical ophthalmic outcome information comprises updating the database with available ophthalmic correction outcome information and optimizing the historical outcome information.

45. The method of claim 42 , wherein optimizing the historical outcome information comprises a statistical analysis of the historical outcome information.

46. The method of claim 45 , wherein optimizing the historical outcome information comprises engaging a neural network to analyze the historical outcome information and the available historical outcome information.

47. The method of claim 42 , wherein the step of maintaining a database of optimized, historical ophthalmic outcome information comprises acquiring new historical outcome information from a third party for a fee.

48. The method of claim 42 , wherein the step of providing a predictive best instruction on a transactional basis comprises receiving a fee or other remuneration.

49. A computer-readable or device-readable medium having stored thereon an executable instruction that is intended to provide a predictive outcome for a therapeutic ophthalmic correction, wherein said instruction is a predicted best instruction that is derived from an analysis of a new information metric relating to an ophthalmic condition of a patient, in conjunction with an optimized, historical, therapeutic-outcome information metric.

50. The medium of claim 49 , wherein the executable instruction is an algorithm that describes a laser ablation shot placement pattern on a patient's eye.

51. The system of claim 49 , wherein the predictive best instruction comprises an outcome-predictive, ophthalmic information metric suited for use by a practitioner for providing the therapeutic ophthalmic correction.

52. A data structure associated with a computing device that generates a predictive best instruction for a therapeutic ophthalmic correction, said data structure performing a method comprising the steps of:

a) receiving a new information metric, said new information metric relating to an ophthalmic defect condition of a patient;

b) maintaining a database of optimized historical ophthalmic outcome information, said ophthalmic outcome information being related to the ophthalmic defect condition; and

c) generating a predictive best instruction for the therapeutic ophthalmic correction.

53. The data structure of claim 52 , wherein the predictive best instruction is provided on a transactional basis.

54. The data structure of claim 53 , wherein the step of providing a predictive best instruction on a transactional basis comprises receiving a fee or other remuneration.

55. The data structure of claim 52 , wherein the step of obtaining a new information metric comprises collecting wavefront aberration data from a wavefront sensor device.

56. The data structure of claim 52 , wherein the step of maintaining a database of optimized, historical ophthalmic outcome information comprises updating the database with available ophthalmic correction outcome information and optimizing the historical outcome information.

57. The data structure of claim 56 , wherein optimizing the historical outcome information comprises a statistical analysis of the historical outcome information.

58. The data structure of claim 56 , wherein optimizing the historical outcome information comprises engaging a neural network to analyze the historical outcome information and the available historical outcome information.

59. The data structure of claim 52 , wherein the step of maintaining a database of optimized, historical ophthalmic outcome information comprises acquiring new historical outcome information from a third party for a fee.

60. The system of claim 1 , wherein the optimization analysis is a finite element analysis (FEA) utilizing a finite element model (FEM), further wherein the FEM is a three-dimensional, anisotropic, nonlinear, viscoelastic layered element.

61. The system of claim 15 , wherein the optimization analysis is a finite element analysis (FEA) utilizing a finite element model (FEM), further wherein the FEM is a three-dimensional, anisotropic, nonlinear, viscoelastic layered element.

62. The system of claim 26 , wherein the optimization analysis is a finite element analysis (FEA) utilizing a finite element model (FEM), further wherein the FEM is a three-dimensional, anisotropic, nonlinear, viscoelastic layered element.

63. The method of claim 37 , wherein the generating step comprises performing a finite element analysis (FEA) utilizing a finite element model (FEM), further wherein the FEM is a three-dimensional, anisotropic, nonlinear, viscoelastic layered element.

Assignments (26)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
Reel/Frame 073637/0126 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
Reel/Frame 073654/0242 →
ASSIGNMENT OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (059913/0548) Recorded Aug 14, 2025
From: CITIBANK, N.A., AS RESIGNING AGENT
To: JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT
Reel/Frame 072469/0091 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
PATENT SECURITY AGREEMENT Recorded Oct 4, 2023
From: BAUSCH & LOMB INCORPORATED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 065120/0086 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 059121/0001) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 061873/0001 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 043251/0932) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH
Reel/Frame 061872/0099 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 045444/0634) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; LABORATOIRE CHAUVIN S.A.S.; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 061872/0295 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 048556/0758) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH COMPANIES INC.; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 061872/0484 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 056811/0814) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 061872/0669 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 031156/0508) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 061778/0446 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 034749/0689) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; UNIVERSITY OF ROCHESTER
Reel/Frame 061778/0146 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 045444/0299) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; PF CONSUMER HEALTHCARE 1 LLC; LABORATOIRE CHAUVIN S.A.S.
Reel/Frame 061779/0001 →
PATENT SECURITY AGREEMENT Recorded May 10, 2022
From: BAUSCH & LOMB INCORPORATED
To: CITIBANK, N.A. AS COLLATERAL AGENT
Reel/Frame 059913/0548 →
SECURITY AGREEMENT Recorded Feb 10, 2022
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 059121/0001 →
SECURITY INTEREST Recorded Jun 8, 2021
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 056811/0814 →
SECURITY INTEREST Recorded Mar 11, 2019
From: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 048556/0758 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
SECURITY INTEREST Recorded Jul 19, 2017
From: BAUSCH & LOMB INCORPORATED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043251/0932 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Sep 4, 2013
From: BAUSCH & LOMB INCORPORATED
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 031156/0508 →
RELEASE OF SECURITY INTEREST Recorded Aug 13, 2013
From: CITIBANK N.A., AS ADMINISTRATIVE AGENT
To: WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.); BAUSCH & LOMB INCORPORATED; ISTA PHARMACEUTICALS
Reel/Frame 030995/0444 →
SECURITY AGREEMENT Recorded Aug 6, 2012
From: BAUSCH & LOMB INCORPORATED; EYEONICS, INC.
To: CITIBANK N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 028728/0645 →
RELEASE OF SECURITY INTEREST Recorded Aug 5, 2012
From: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 028726/0142 →